Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide and is
predicted to become second in 2030 in industrialized countries if no therapeutic progress is …

Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

Pancreatic cancer (PC) is a devastating disease, offering poor mortality rates for patients.
The current challenge being faced is the inability to diagnose patients in a timely manner …

Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal
myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the …

Pancreatic ductal adenocarcinoma (PDA) is the most lethal of common human
malignancies, with no truly effective therapies for advanced disease. Preclinical studies …

The characteristic desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC) is a
key contributor to its lethality. This stromal microenvironment is populated by cancer …

Curcumin (CUR), a naturally occurring polyphenol derived from the root of Curcuma longa,
has showed potent anticancer and cancer prevention activity in a variety of cancers …

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer
with an abysmal prognosis rate over the last few decades. Early diagnosis and prevention …

Stromal cells residing in the tumor microenvironment contribute to the development of
therapy resistance. Here we show that chemotherapy-educated mesenchymal stem cells …

Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …